Lapatinib (INN), used in the form of lapatinib ditosylate, (USAN) (Tykerb/Tyverb, GSK) is an orally active drug for breast cancer and other solid tumours. It is a dual tyrosine kinase inhibitor which interrupts the HER2 growth receptor pathway. It is used in combination therapy for HER2-positive breast cancer. It has been approved as front-line therapy in triple positive breast cancer and as an adjuvant therapy when patients have progressed on Herceptin.
This text uses material from Wikipedia, licensed under CC BY-SA
Sorry, no news articles match your request
About
Phys.org™ is a leading web-based science, research and technology news service which covers a full range of topics.
Phys.org is a part of Science X network. With a global reach of over 10 million monthly readers and featuring dedicated websites for science (Phys.org), technology (Tech Xplore) and medical research (Medical Xpress), the Science X network is one of the largest online communities for science-minded people.
Read moreIdentify the news topics you want to see and prioritize an order.
Science never stops. Get notified about trending stories.